AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20307355 — intervention group
Group type: COMPARATOR
Intervention: 40 g casein (placebo; Trp:LNAA ratio of 4.0)
Number of subjects: 25
Study 18262575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 M sucrose solution
Number of subjects: 20
Study 18262575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet flavours (orange juice, coke, lemonade)
Number of subjects: 20
Study 18262575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 M NaCl solution (unpleasant stimulus)
Number of subjects: 20
Study 18262575 — intervention group
Group type: EXPERIMENTAL
Intervention: Evian mineral water (neutral stimulus)
Number of subjects: 20
Study 16792438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1000
Study 16792438 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1000
Study 12792136 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 34
Study 12792136 — intervention group
Group type: COMPARATOR
Intervention: timolol
Number of subjects: 34
Study 11235004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic conditioning program (24 women)
Number of subjects: 34
Study 11235004 — intervention group
Group type: COMPARATOR
Intervention: No sports activity (10 women)
Number of subjects: 34
Study 11235004 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 34
Study 8639883 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group)
Number of subjects: 121
Study 8639883 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step‐wise escalation of the rhEPO dose (titration group)
Number of subjects: 121
Study 8639883 — intervention group
Group type: COMPARATOR
Intervention: no rhEPO therapy (control group)
Number of subjects: 121
Study 1598788 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 x 10(9) live bacteria
Number of subjects: 21
Study 1598788 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses every other day of 2 x 10(9) live bacteria
Number of subjects: 21
Study 1598788 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of 2 x 10(9) bacteria
Number of subjects: 21
Study 1598788 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of the vaccine
Number of subjects: 21
Study 1598788 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exposure to shigellae
Number of subjects: 21
Study 6529523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (450 mg single oral dose)
Number of subjects: 10
Study 6529523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (450 mg twice daily)
Number of subjects: 10
Study 6529523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30446783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 107
Study 30446783 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 107
Study 30446783 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort (ET and APM combined)
Number of subjects: 107
Study 30205493 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose meal
Number of subjects: 16
Study 30205493 — intervention group
Group type: COMPARATOR
Intervention: Low fructose meal
Number of subjects: 16
Study 26993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilizumab (300 mg monthly)
Number of subjects: 578
Study 26993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilizumab (monthly or quarterly dosing)
Number of subjects: 578
Study 26993628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study 25276983 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnaojing Injection combined with minimally invasive percutaneous drainage
Number of subjects: 42
Study 25276983 — intervention group
Group type: COMPARATOR
Intervention: Control group (minimally invasive percutaneous drainage only)
Number of subjects: 42
Study 22742438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy for 30 min every morning during chemotherapy
Number of subjects: 39
Study 22742438 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy for 30 min every morning during chemotherapy
Number of subjects: 39
Study 22742438 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy
Number of subjects: 39
Study 22742438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy
Number of subjects: 39
Study 19656432 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS to the left temporal cortex
Number of subjects: 18
Study 19656432 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS to the right temporal cortex
Number of subjects: 18
Study 19656432 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS to the vertex (control condition)
Number of subjects: 18
Study 19656432 — intervention group
Group type: EXPERIMENTAL
Intervention: Open continued treatment phase
Number of subjects: 18
Study 17509068 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care (hospital outpatient clinic with initial 6 months' lifestyle programme followed by intensified pharmacological treatment)
Number of subjects: 120
Study 17509068 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care
Number of subjects: 120
Study 17509068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified pharmacological treatment (6-24 months)
Number of subjects: 120
Study 17509068 — intervention group
Group type: COMPARATOR
Intervention: Standard care (follow-up by general practitioner)
Number of subjects: 120
Study 15843080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 800 mg/day for 10 days
Number of subjects: 32
Study 15843080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet without milk for 40 days
Number of subjects: 32
Study 15843080 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 32
Study 11860405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg b.d. alosetron
Number of subjects: 36
Study 11860405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg b.d. alosetron
Number of subjects: 36
Study 11860405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10206459 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen 1
Number of subjects: 118
Study 10206459 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen 2
Number of subjects: 118
Study 10206459 — intervention group
Group type: COMPARATOR
Intervention: Control group (not transfused before surgery)
Number of subjects: 118
Study 7703878 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively negotiated process of decision making (n = 53)
Number of subjects: 98
Study 7703878 — intervention group
Group type: COMPARATOR
Intervention: Nonnegotiated approach (n = 45)
Number of subjects: 98
Study 2720192 — intervention group
Group type: EXPERIMENTAL
Intervention: GUIDELINES (three sessions of advice using a pamphlet)
Number of subjects: 90
Study 2720192 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual (three sessions of instruction in the use of a 'self‐help' manual)
Number of subjects: 90
Study 2720192 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist (six or more sessions of instruction in the methods outlined in the 'self‐help' manual)
Number of subjects: 90
Study 2720192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 90
Study 2720192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (1-year follow-up)
Number of subjects: 90
Study 805651 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 0
Study 805651 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 31868791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternation flicker format
Number of subjects: 286
Study 31868791 — intervention group
Group type: COMPARATOR
Intervention: Side-by-side layout
Number of subjects: 286
Study 31868791 — intervention group
Group type: COMPARATOR
Intervention: Up-and-down layout
Number of subjects: 286
Study 30924890 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling through a range of activities and home visits for a mean duration of 5.5 years
Number of subjects: 650
Study 30924890 — intervention group
Group type: COMPARATOR
Intervention: No special services
Number of subjects: 650
Study 27267614 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 2 receptor antagonist
Number of subjects: 200
Study 27267614 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin induction
Number of subjects: 200
Study 27267614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low and high panel reactive antibody)
Number of subjects: 200
Study 25686324 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (SRP + antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days)
Number of subjects: 30
Study 25686324 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (SRP followed by antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days starting 1 day after SRP)
Number of subjects: 30
Study 25686324 — intervention group
Group type: COMPARATOR
Intervention: Group C (SRP alone)
Number of subjects: 30
Study 25686324 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 30
Study 25686324 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 30
Study 25686324 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A, Group B, Group C
Number of subjects: 30
Study 21815995 — intervention group
Group type: EXPERIMENTAL
Intervention: Block bone grafts
Number of subjects: 15
Study 21815995 — intervention group
Group type: COMPARATOR
Intervention: Particulate bone grafts
Number of subjects: 15
Study 21815995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 15
Study 21803755 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory modulation (RM) device, 20 min sessions twice daily for 4 weeks
Number of subjects: 72
Study 21803755 — intervention group
Group type: COMPARATOR
Intervention: Music listening (ML) using a CD player, control group
Number of subjects: 72
Study 19552750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from a clinical pharmacist
Number of subjects: 240
Study 19552750 — intervention group
Group type: COMPARATOR
Intervention: Usual care from medical and nursing staff
Number of subjects: 240
Study 16963348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition practice guidelines care (12 sites)
Number of subjects: 215
Study 16963348 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition care (13 sites)
Number of subjects: 215
Study 15589864 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg anastrozole
Number of subjects: 26
Study 15589864 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg anastrozole
Number of subjects: 26
Study 15589864 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg anastrozole
Number of subjects: 26
Study 15589864 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg anastrozole
Number of subjects: 26
Study 15589864 — intervention group
Group type: EXPERIMENTAL
Intervention: five daily doses of 10 mg or 15 mg anastrozole
Number of subjects: 26
Study 15589864 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study 12359281 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 0.1 mg/Kg chlorpromazine (CPZ)
Number of subjects: 128
Study 12359281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 9795928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol nasal spray
Number of subjects: 48
Study 9795928 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48
Study 7900512 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in fat and lactose
Number of subjects: 143
Study 7900512 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 143
Study 2468628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral information
Number of subjects: 0
Study 2468628 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 0
Study 2468628 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide-tape based information
Number of subjects: 0
Study 2468628 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-sound based information
Number of subjects: 0
Study 2468628 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap estimation
Number of subjects: 0
Study 335490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for four weeks
Number of subjects: 58
Study 335490 — intervention group
Group type: COMPARATOR
Intervention: Inactive tablets (control)
Number of subjects: 58
Study 335490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 58
Study 31278094 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day trans-resveratrol for 8 weeks
Number of subjects: 72
Study 31278094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl cellulose) for 8 weeks
Number of subjects: 72
Study 31278094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (trans-resveratrol and placebo)
Number of subjects: 72
Study 28638702 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day Rosuvastatin
Number of subjects: 50
Study 28638702 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day Rosuvastatin
Number of subjects: 50
Study 25781872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute rest interval (RI)
Number of subjects: 30
Study 25781872 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minute rest interval (RI)
Number of subjects: 30
Study 25781872 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNT)
Number of subjects: 30
Study 23518825 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (tonsillectomy and/or adenoidectomy; n = 32)
Number of subjects: 112
Study 23518825 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical group (n = 76)
Number of subjects: 112
Study 21851618 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch screen version of questionnaires
Number of subjects: 20
Study 21851618 — intervention group
Group type: COMPARATOR
Intervention: Paper version of questionnaires
Number of subjects: 20
Study 19526755 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI)
Number of subjects: 40
Study 19526755 — intervention group
Group type: COMPARATOR
Intervention: Control (Ringer's Liquid)
Number of subjects: 40
Study 17707898 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training program (hybrid website/CD-ROM training, seminar series, companion intervention material, clinic mobilization)
Number of subjects: 16
Study 17707898 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training program
Number of subjects: 16
Study 17707898 — intervention group
Group type: COMPARATOR
Intervention: Standard training (seminar series and standard educational/self-help material)
Number of subjects: 16
Study 15291686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171
Study 15291686 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study 11491417 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir placebo (three times per day)
Number of subjects: 105
Study 11491417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir (750 mg three times per day)
Number of subjects: 105
Study 11491417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/nelfinavir (after switching from double nucleoside therapy)
Number of subjects: 105
Study 11491417 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day)
Number of subjects: 105
Study 9635807 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐arm image intensifier
Number of subjects: 197
Study 9635807 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 197
Study 7963648 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids applied topically immediately after UVB irradiation
Number of subjects: 16
Study 7963648 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin applied topically immediately after UVB irradiation
Number of subjects: 16
Study 29987421 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 436
Study 29987421 — intervention group
Group type: COMPARATOR
Intervention: Control (no EVT)
Number of subjects: 436
Study 29987421 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up infarct volume (FIV)
Number of subjects: 436
Study 29987421 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) after adjustment for FIV
Number of subjects: 436
Study 29158670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation (SS)
Number of subjects: 43
Study 29158670 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 43
Study 26051365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1106
Study 26051365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1106
Study 26051365 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 1106
Study 26051365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study 23664040 — intervention group
Group type: EXPERIMENTAL
Intervention: Light emitting diode therapy (LEDT)
Number of subjects: 18
Study 23664040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21859685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg (two infusions, 2 weeks apart)
Number of subjects: 260
Study 21859685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 21859685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 260
Study 17610057 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatis Method (Treatment)
Number of subjects: 0
Study 17610057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 16859505 — intervention group
Group type: COMPARATOR
Intervention: Recombinant activated factor VII (rFVIIa) at an initial dose of 200 microg x kg‐1 after transfusion of eight red blood cell units, followed by additional doses of 100 microg x kg‐1, one and three hours later
Number of subjects: 0
Study 12580652 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20
Study 12580652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11193130 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal group (W), n = 21
Number of subjects: 45
Study 11193130 — intervention group
Group type: COMPARATOR
Intervention: Continued medication group (C), n = 24
Number of subjects: 45
Study 9083600 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Workshop
Number of subjects: 0
Study 9083600 — intervention group
Group type: COMPARATOR
Intervention: Information Workshop
Number of subjects: 0
Study 9083600 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leaders portrayed as similar
Number of subjects: 0
Study 9083600 — intervention group
Group type: COMPARATOR
Intervention: Peer leaders portrayed as dissimilar
Number of subjects: 0
Study 8473466 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Trp6 LHRH microcapsules (i.m. injection) at 2 months and 1 month prior to surgery
Number of subjects: 53
Study 8473466 — intervention group
Group type: COMPARATOR
Intervention: No pre‐operative treatment (control group)
Number of subjects: 53
Study 3964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.2 mg)
Number of subjects: 20
Study 3964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine (0.15 mg)
Number of subjects: 20
Study 3964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes (sublingual and i.m.)
Number of subjects: 20
Study 3964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 20
Study 3964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine
Number of subjects: 20
Study 29776559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg
Number of subjects: 8432
Study 29776559 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 8432
Study 26853286 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 30
Study 26853286 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine + Vasopressin (0.03 u/min)
Number of subjects: 30
Study 24851690 — intervention group
Group type: EXPERIMENTAL
Intervention: CT diagnostic standard derived from Group A (n = 101) measuring size of lesion, proportion of GGO composition, long diameter, longest diameter, and size of solid component.
Number of subjects: 143
Study 24851690 — intervention group
Group type: COMPARATOR
Intervention: CT diagnostic standard applied to Group B (n = 42) for evaluating accuracy.
Number of subjects: 143
Study 22446632 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer needle length (1 in.)
Number of subjects: 59
Study 22446632 — intervention group
Group type: COMPARATOR
Intervention: Standard needle length (5/8 in.)
Number of subjects: 59
Study 20015788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (LVFX)
Number of subjects: 93
Study 20015788 — intervention group
Group type: COMPARATOR
Intervention: Intravenous flomoxef (FMOX)
Number of subjects: 93
Study 18805102 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coronary artery revascularization
Number of subjects: 1048
Study 16276137 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (walking 3 d/wk and resistance exercises 2 d/wk for 40-60 minutes)
Number of subjects: 31
Study 16276137 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 31